HRP20180341T1 - Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd - Google Patents

Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd Download PDF

Info

Publication number
HRP20180341T1
HRP20180341T1 HRP20180341TT HRP20180341T HRP20180341T1 HR P20180341 T1 HRP20180341 T1 HR P20180341T1 HR P20180341T T HRP20180341T T HR P20180341TT HR P20180341 T HRP20180341 T HR P20180341T HR P20180341 T1 HRP20180341 T1 HR P20180341T1
Authority
HR
Croatia
Prior art keywords
pyrazol
hydroxy
pyridin
carbonyl
methylbenzonitrile
Prior art date
Application number
HRP20180341TT
Other languages
English (en)
Inventor
Jason W. Brown
Melinda DAVIS
Anthony IVETAC
Benjamin Jones
Andre A. Kiryanov
Jon KUEHLER
Marion Lanier
Joanne Miura
Sean Murphy
Xiaolun Wang
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HRP20180341T1 publication Critical patent/HRP20180341T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)

Claims (17)

1. Spoj prema formuli [image] ili njegova farmaceutski prihvatljiva sol, naznačen time da q je 0, 1, ili 2; s je 0, 1, ili 2; R3, svaki puta, je neovisno odabran iz skupine koju čine vodik, hidroksil, amino, C1-8 alkilamino, cijano, halo, proizvoljno supstituiran C1-6 alkil, i C1-4 alkoksi; R4 je odabran iz skupine koju čine vodik, cijano, halo, metil, etil, metoksi, i trifluorometil; R5 je odabran iz skupine koju čine [image] G je ugljik; A je odabran iz skupine koju čine N, O, S, CR6 i NR6; E je odabran iz skupine koju čine N, O, S, i CR6; pod uvjetom da samo jedan od A i E može biti O ili S; ili G je N i A i E su CR6; ili G i A su N i E je CR6; ili G, A, i E su N; R6, svaki puta, je neovisno odabran iz skupine koju čine vodik, cijano, halo, C3-8 cikloalkil, proizvoljno supstituiran C1-6 alkil, C1-4 alkoksi, i trifluorometil; R7 je odabran iz skupine koju čine cijano i cijanometil; R8, svaki puta, je neovisno odabran iz skupine koju čine vodik, cijano, halo, C1-4 alkil, C1-4 alkoksi, i trifluorometil; i R9 je odabran iz skupine koju čine vodik, C1-6 alkil proizvoljno supstituiran s 1 do 3 fluoro, i C3-8 cikloalkil.
2. Spoj ili farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da R5 je [image] .
3. Spoj ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 ili 2, naznačen time da R9 je C1-6 alkil.
4. Spoj ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 3, naznačen time da s je 1 i q je 1.
5. Spoj ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 4, naznačen time da svaki R8 je vodik.
6. Spoj ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 4, naznačen time da jedan od R8 je C1-4 alkil i svaki drugi R8 je vodik.
7. Spoj ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 4, naznačen time da jedan od R8 je metil i svaki drugi R8 je vodik.
8. Spoj ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 7, naznačen time da svaki R3 je vodik i R4 je vodik.
9. Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koju čine: 4-(1-(5-(4-etilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(4-propilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(4-metil-1,4-diazepane-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(4-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(4-(tert-butil)piperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(6,6-difluoro-4-metil-1,4-diazepane-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(4-etilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; 4-(1-(5-(4-etilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; 4-(1-(5-(4-ciklopropilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; 4-(1-(5-(4-ciklopropilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; 4-(1-(5-(4-etilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2,3-dimetilbenzonitril; 4-(1-(5-(4-ciklopropilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2,3-dimetilbenzonitril; 4-(1-(5-(4-(2,2-difluoroetil)piperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(4-(2,2,2-trifluoroetil)piperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 2-fluoro-4-(5-hidroksi-1-(5-(4-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(4-ciklopropil-1,4-diazepane-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; (S)-4-(1-(5-(4-etil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; 4-(1-(5-(4-etil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; (S)-4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; 4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; (R)-4-(1-(5-(4-etil-2-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; 4-(1-(5-(4-etil-2-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; (R)-2-fluoro-4-(5-hidroksi-1-(5-(4-izopropil-3-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 2-fluoro-4-(5-hidroksi-1-(5-(4-izopropil-3-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; (R)-4-(1-(5-(4-etil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; (S)-2-fluoro-4-(5-hidroksi-1-(5-(4-izopropil-3-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; (R)-4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; (S)-4-(1-(5-(4-etil-2-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(4-(pentan-3-il)piperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; (S)-4-(1-(5-(4-etil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(4-etil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; (S)-4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(4-ciklobutilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; (S)-4-(5-hidroksi-1-(5-(3-metil-4-propilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; (R)-4-(5-hidroksi-1-(5-(3-metil-4-propilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(3-metil-4-propilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; (R)-4-(1-(5-(4-ciklopropil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1 H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(4-ciklopropil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(3,3,4-trimetilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(4-etil-3,3-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; (R)-4-(5-hidroksi-1-(5-(4-izopropil-3-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(4-izopropil-3-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; (R)-4-(1-(5-(2,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(1-(5-(2,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; (R)-4-(1-(5-(4-etil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; (S)-4-(1-(5-(4-ciklopropil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; (S)-4-(1-(5-(2,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; (R)-4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; (S)-4-(5-hidroksi-1-(5-(4-izopropil-3-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; (R)-4-(1-(5-(4-etil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; 4-(1-(5-(4-etil-3-metilpiperazin-1 -karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; 2-fluoro-4-(5-hidroksi-1-(5-(4-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-5-metilbenzonitril; (S)-4-(1-(5-(4-etil-3-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; (S)-4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; (R)-4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; 4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; 4-(1-(5-(4-ciklopropilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(4-propilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(5-(4-propil-1,4-diazepane-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril; 4-(5-hidroksi-1-(4-metil-5-(4-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)benzonitril; (S)-4-(1-(5-(4-etil-2-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; (R)-4-(1-(5-(4-etil-2-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; 4-(1-(5-(4-etil-2-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-2-fluoro-5-metilbenzonitril; (R)-4-(1-(5-(4-etil-2-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; (S)-4-(1-(5-(4-etil-2-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; i 4-(1-(5-(4-etil-2-metilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril; i farmaceutski prihvatljiva sol bilo kojeg od gore navedenih spojeva.
10. Spoj prema zahtjevu 1, naznačen time da je 4-(1-(5-(4-etilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril ili njegova farmaceutski prihvatljiva sol.
11. Spoj prema zahtjevu 1, naznačen time da je 4-(5-hidroksi-1-(5-(4-metilpiperazin-1-karbonil)piridin-2-il)-1H-pirazol-4-il)-3-metilbenzonitril ili njegova farmaceutski prihvatljiva sol.
12. Spoj prema zahtjevu 1, naznačen time da je 4-(1-(5-(4-(2,2-difluoroetil)piperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril ili njegova farmaceutski prihvatljiva sol.
13. Spoj prema zahtjevu 1, naznačen time da je (S)-4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril ili njegova farmaceutski prihvatljiva sol.
14. Spoj prema zahtjevu 1, naznačen time da je (R)-4-(1-(5-(2,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril ili njegova farmaceutski prihvatljiva sol.
15. Spoj prema zahtjevu 1, naznačen time da je (R)-4-(1-(5-(3,4-dimetilpiperazin-1-karbonil)piridin-2-il)-5-hidroksi-1H-pirazol-4-il)-3-metilbenzonitril ili njegova farmaceutski prihvatljiva sol.
16. Farmaceutski pripravak naznačen time da sadrži spoj ili farmaceutski prihvatljivu sol kako je definirano u bilo kojem od zahtjeva 1 do 15, i farmaceutski prihvatljivo pomoćno sredstvo.
17. Spoj ili farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 15 naznačen time da je za uporabu kao lijek.
HRP20180341TT 2013-03-29 2018-02-26 Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd HRP20180341T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361806806P 2013-03-29 2013-03-29
US201361916715P 2013-12-16 2013-12-16
PCT/US2014/031918 WO2014160810A1 (en) 2013-03-29 2014-03-26 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
EP14726246.3A EP2978752B1 (en) 2013-03-29 2014-03-26 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors

Publications (1)

Publication Number Publication Date
HRP20180341T1 true HRP20180341T1 (hr) 2018-04-20

Family

ID=50792544

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180341TT HRP20180341T1 (hr) 2013-03-29 2018-02-26 Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd

Country Status (40)

Country Link
US (5) US9040522B2 (hr)
EP (2) EP3336084B1 (hr)
JP (4) JP6282724B2 (hr)
KR (1) KR102376354B1 (hr)
CN (1) CN105492433B (hr)
AP (1) AP2015008783A0 (hr)
AU (1) AU2014241183B2 (hr)
BR (1) BR112015020350B1 (hr)
CA (1) CA2903875C (hr)
CL (1) CL2015002473A1 (hr)
CR (1) CR20150517A (hr)
CY (1) CY1120029T1 (hr)
DK (1) DK2978752T3 (hr)
EA (1) EA031647B1 (hr)
EC (1) ECSP15045801A (hr)
ES (1) ES2660914T3 (hr)
GE (1) GEP201706761B (hr)
HK (1) HK1217701A1 (hr)
HR (1) HRP20180341T1 (hr)
HU (1) HUE038220T2 (hr)
IL (1) IL240803B (hr)
JO (1) JO3722B1 (hr)
LT (1) LT2978752T (hr)
ME (1) ME03024B (hr)
MX (1) MX370388B (hr)
MY (1) MY184218A (hr)
PE (1) PE20151860A1 (hr)
PH (1) PH12015502248A1 (hr)
PL (1) PL2978752T3 (hr)
PT (1) PT2978752T (hr)
RS (1) RS56974B1 (hr)
SG (1) SG11201506749XA (hr)
SI (1) SI2978752T1 (hr)
TN (1) TN2015000397A1 (hr)
TR (1) TR201802632T4 (hr)
TW (1) TWI635084B (hr)
UA (1) UA118965C2 (hr)
UY (1) UY35513A (hr)
WO (1) WO2014160810A1 (hr)
ZA (1) ZA201506484B (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660914T3 (es) * 2013-03-29 2018-03-26 Takeda Pharmaceutical Company Limited Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD
AU2015328174B2 (en) 2014-10-06 2020-05-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR102531491B1 (ko) 2016-09-30 2023-05-10 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조절제, 제약 조성물, 치료 방법, 및 상기 조절제의 제조 방법
JOP20190125B1 (ar) 2016-12-09 2022-03-14 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN107163043A (zh) * 2017-06-16 2017-09-15 上海毕得医药科技有限公司 一种吡唑并[1,5‑a]吡啶‑3‑羧酸酯衍生物的合成方法
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
AU2018309043B2 (en) 2017-08-02 2022-03-31 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
JP7245834B2 (ja) 2017-12-08 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
CN111918865B (zh) 2018-03-30 2023-10-27 住友化学株式会社 杂环化合物和含有该杂环化合物的有害节肢动物防除组合物
WO2019195739A1 (en) * 2018-04-05 2019-10-10 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020156571A1 (zh) * 2019-02-02 2020-08-06 杭州华东医药集团新药研究院有限公司 一种哒嗪衍生物及其制备方法和医药用途
JP2023518262A (ja) * 2020-03-20 2023-04-28 アケビア セラピューティクス インコーポレイテッド Ｐｈｄ阻害剤化合物、組成物、及び使用
IL296631A (en) * 2020-03-20 2022-11-01 Akebia Therapeutics Inc phd inhibitory compounds, compositions and use
US20230212138A1 (en) * 2020-03-20 2023-07-06 Akebia Therapeutics, Inc. Phd inhibitor compounds, compositions, and their use
TW202200134A (zh) 2020-04-20 2022-01-01 美商阿克比治療有限公司 治療病毒感染、器官損傷及相關症狀之方法
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20040067955A1 (en) * 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
MX2008002063A (es) 2005-08-19 2008-04-16 Astrazeneca Ab Derivados de pirazolona para el tratamiento de tuberculosis.
PL3357911T3 (pl) * 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
KR101404360B1 (ko) * 2006-09-05 2014-06-09 교와 핫꼬 기린 가부시키가이샤 이미다졸 유도체
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
RU2485114C2 (ru) 2006-12-29 2013-06-20 Эбботт Гмбх Унд Ко.Кг Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов
DE102007044032A1 (de) 2007-09-14 2009-03-19 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
JP5557832B2 (ja) * 2008-03-18 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換４−ヒドロキシピリジン−５−カルボキサミド
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
DK2382215T3 (da) * 2008-12-29 2014-10-27 Sanofi Sa Derivater af 2-pyridin-2-yl-pyrazol-3(2h)-on, fremstilling og terapeutisk anvendelse heraf
JP5734870B2 (ja) * 2008-12-29 2015-06-17 サノフイ ２−ピリジン−２−イル−ピラゾール−３（２ｈ）−オンの誘導体、これらの調製およびｈｉｆ活性化剤としての治療用途
ES2660914T3 (es) * 2013-03-29 2018-03-26 Takeda Pharmaceutical Company Limited Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD

Also Published As

Publication number Publication date
AU2014241183A1 (en) 2015-09-24
KR20150135794A (ko) 2015-12-03
HK1217701A1 (zh) 2017-01-20
CN105492433A (zh) 2016-04-13
LT2978752T (lt) 2018-03-26
JP2019069997A (ja) 2019-05-09
MX2015013687A (es) 2016-02-25
TWI635084B (zh) 2018-09-11
US9345713B2 (en) 2016-05-24
US20150224113A1 (en) 2015-08-13
RS56974B1 (sr) 2018-05-31
NZ711522A (en) 2021-02-26
US20170275271A1 (en) 2017-09-28
GEP201706761B (en) 2017-10-25
EP3336084A1 (en) 2018-06-20
JP2020073538A (ja) 2020-05-14
MY184218A (en) 2021-03-26
HUE038220T2 (hu) 2018-10-29
CA2903875A1 (en) 2014-10-02
CY1120029T1 (el) 2018-12-12
JP6640978B2 (ja) 2020-02-05
ZA201506484B (en) 2017-11-29
JP2018083838A (ja) 2018-05-31
CN105492433B (zh) 2018-11-23
US9944626B2 (en) 2018-04-17
TW201446752A (zh) 2014-12-16
TN2015000397A1 (en) 2017-01-03
SI2978752T1 (en) 2018-04-30
KR102376354B1 (ko) 2022-04-04
EP3336084B1 (en) 2021-03-17
US20160251337A1 (en) 2016-09-01
US9040522B2 (en) 2015-05-26
IL240803A0 (en) 2015-10-29
JP6462911B2 (ja) 2019-01-30
US20180186772A1 (en) 2018-07-05
ES2660914T3 (es) 2018-03-26
ECSP15045801A (es) 2017-02-24
JP6874114B2 (ja) 2021-05-19
EA201591889A1 (ru) 2016-01-29
BR112015020350A2 (pt) 2017-07-18
JP6282724B2 (ja) 2018-02-21
US20140296200A1 (en) 2014-10-02
PT2978752T (pt) 2018-03-09
WO2014160810A1 (en) 2014-10-02
ME03024B (me) 2018-10-20
PH12015502248B1 (en) 2016-02-01
JO3722B1 (ar) 2021-01-31
US9708296B2 (en) 2017-07-18
PH12015502248A1 (en) 2016-02-01
CA2903875C (en) 2021-07-20
PL2978752T3 (pl) 2018-06-29
CR20150517A (es) 2016-01-12
AU2014241183B2 (en) 2018-08-09
CL2015002473A1 (es) 2016-08-26
US10407409B2 (en) 2019-09-10
EP2978752B1 (en) 2017-11-29
MX370388B (es) 2019-12-11
UA118965C2 (uk) 2019-04-10
TR201802632T4 (tr) 2018-03-21
UY35513A (es) 2014-10-31
PE20151860A1 (es) 2015-12-16
BR112015020350B1 (pt) 2023-04-25
IL240803B (en) 2019-02-28
DK2978752T3 (en) 2018-03-12
SG11201506749XA (en) 2015-09-29
EA031647B1 (ru) 2019-02-28
EP2978752A1 (en) 2016-02-03
JP2016515582A (ja) 2016-05-30
AP2015008783A0 (en) 2015-10-31

Similar Documents

Publication Publication Date Title
HRP20180341T1 (hr) Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd
AU2018256624A1 (en) JAK2 and ALK2 inhibitors and methods for their use
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
FR22C1053I2 (fr) Composes et compositions pour inhiber l'activite d'abl1, abl2 et bcr-abl1
IL291489A (en) Preparation of (s)-4-(8-amino-3-(1-but-2-inoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridine- 2-l) Benzamide and its acceptable pharmaceutical salts
HRP20180483T1 (hr) Spoj kinolona
MX2021002257A (es) Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
SI2576523T1 (sl) Kristalinične oblike 4-(5-(3-kloro-5-(trifluorometil)fenil)-4,5-dihidro 5-(trifluorometil)-3-izoksazolil)-N-(2-okso-2-((2,2,2-trifluoroetil) amino)etil)-1 naftalenkarboksamida
JP2016515582A5 (hr)
IN2014MN01754A (hr)
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
CO7051030A2 (es) Formulaciones farmacéuticas novedosas
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
RU2015155585A (ru) 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента
WO2013012485A3 (en) Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
PH12018501531A1 (en) Pyrazole compounds as crth2 antagonists
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
WO2014062838A3 (en) Pkm2 modulators and methods for their use
PH12017501750A1 (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
MD4563C1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
HRP20180386T1 (hr) Farmaceutski aktivni spojevi
PH12016500134B1 (en) 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives
IL225105A (en) Heterocyclic compounds, their process, their pharmaceutical preparations and their use in the preparation of drugs
PH12014502609A1 (en) Mutilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
WO2013057569A3 (en) Extended release pharmaceutical composition containing amoxicillin and clavulanic acid